Intraoperative Infusion of Dexmedetomidine for Prevention of Postoperative Delirium in Elderly Patients

• Status: Not yet recruiting
• Trial end date: 2024-12-31
• Target enrollment: 0
• Participant gender: All

Summary

Postoperative delirium (POD) is a common complication, and the incidence rate is about 25% in non-cardiac surgery. Previous studies have reported that the total incidence of neurological POD ranged from 10% to 22%. Dexmedetomidine (DEX) is an a-2 adrenergic agonist for sedation. This kind of drug has little effect on respiratory function, is easy to wake up and has analgesic effect. It is a commonly used perioperative adjuvant drug. However, for elderly patients with brain tumors, the role of DEX in POD is not clear. The purpose of this study was to investigate the effect of DEX on POD in in elderly patients undergoing brain tumor resections.

• Phase: N/A
• Accepts Healthy Volunteers?: No

Details

• Lead Sponsor: Beijing Tiantan Hospital
• Treatments: Dexmedetomidine

Criteria

Inclusion Criteria:

• Patients undergoing selective brain tumor resection surgery.

• Age ≥65 years.

• Obtain written informed consent.

Exclusion Criteria:

• Preoperative severe cognitive impairment (mini-mental state examination, MMSE ≤ 20).

• Allergic to the study drug.

• body mass index ≤18 or ≥ 30

• History of psychotropic drugs.

• History of traumatic brain injury or neurosurgery.

• Severe bradycardia (heart rate less than 40 beats per minute), sick sinus syndrome or second-to-third degree atrioventricular block.

• Severe hepatic or renal dysfunction.